1Szlosarek PW, Balkwill FR.Tumour necrosis factor alpha:a potential target for the therapy of solid tumours[J].Lancet Oncol,2003,4:565. 被引量：1
2Hibi T, Inoue N, Ogata H, et al. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease[J]. J Gastroenterol,2003,38(Suppl 15):36. 被引量：1
3Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease[J].N Engl J Med, 1999,340:1398. 被引量：1
4Sands BE,Tremaine WJ,Sandborn WJ,et al.Infliximab in the treatment of severe,steroid-refractory ulcerative colitis:a pilot study[J].Inflamm Bowel Dis,2001,7:83. 被引量：1
5Hanauer SB,Feagan BG, Lichterwein GR, et al. Maintenance infliximab for Crohn's disease.the ACCENT I randomized trial[J]. Lancet,2002,359:1541. 被引量：1
6Rutgeerts P,Feagan BG,Lichterwein GR,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease[J].Gastroenterology, 2004,126:402. 被引量：1
7Sandborn WJ.Strategies for targeting tumour necrosis factor in IBD[J].Best Pract Res Clin Gastroenterol,2003,17:105. 被引量：1
8Farrell R J, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduce antibodies to infliximab in Crohn's disease: a randomized trial[J].Gastroenterology,2003,124:917. 被引量：1
9Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial[J]. Gastroenterology,2001,120:1330. 被引量：1
10Facchini S,Candusso M,Martelossi S,et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results[J].J Pediatr Gastroenterol Nutr,2001,32:178. 被引量：1
